+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Skin Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

  • PDF Icon


  • 111 Pages
  • August 2020
  • Region: Global
  • Mordor Intelligence
  • ID: 4622274
Skin cancer is the most common form of cancer. Even though most types of skin cancers are preventable, its incidence is increasing. The risk factors include sunlight, sunlamps and tanning booths, certain medical conditions, or medicines. The UV radiation changes the genetic material (DNA) in cells and is, therefore, the main cause of skin cancer. The rate of new melanoma cases among both men and women has been increasing at 1.7% and 1.4% per year respectively, as per the data of Federal Centers for Disease Control and Prevention (CDC). Thus, the increasing prevalence of skin cancer is augmenting the growth of the market studied.

Key Market Trends

Non-melanoma skin cancer segment is expected to witness healthy growth in the future

Currently, around 2-3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year. According to the World Cancer Research Fund International, in 2018, non-melanoma skin cancer is the fifth most commonly occurring cancer in people, with over one million diagnosis worldwide. Thus, it is the most common malignancy in the United States, with substantial associated morbidity and cost, as well as relatively small but significant mortality.

According to Cancer Research UK, there are around 147,000 new non-melanoma skin cancer cases in the United Kingdom every year, which is more than 400 every day (2014-2016). In 2016, around 67,700 new cases in females and 88,700 new cases in males have been registered.

Treatment for non-melanoma skin cancer is usually successful, as unlike the other types of cancer, there's a significantly lower risk that the cancer will spread to other parts of the body. Treatment for non-melanoma skin cancer is completely successful in approximately 90% of cases. Hence, the increasing rates of the non-melanoma skin cancer and its successful rates after treatment have helped in the growth of the overall market.

North America dominates the Market and expected to do Same in the Forecast Period

North America is expected to dominate the market in the forecast period. As per the American Academy of Dermatology, skin cancer is the most common cancer in the United States. Most cases of melanoma, the deadliest kind of skin cancer, are caused by exposure to ultraviolet (UV) light. It is estimated that approximately 9,500 people in the United States are diagnosed with skin cancer every day. Furthermore, as per the estimates of the American Cancer Society, in 2018, there were around 91,270 new cases of melanoma in the United States, and approximately 9,320 deaths due to this disease.

Thus, the increasing incidences of skin cancer in the region is a major factor driving the growth of the market studied. Additionally, the recent advancements of skin cancer therapy, including photodynamic therapy (PDT), have been widely used in treating non-melanoma skin malignancies, thus boosting the growth of the market studied during the forecast period.

Competitive Landscape

The global skin cancer diagnostics and therapeutics market is highly competitive and consists of a number of major players. Companies, like Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., among others, hold the substantial market share in the skin cancer diagnostic & therapeutics market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Skin Cancer
4.2.2 Rising Awareness about Skin Cancer
4.2.3 Extensive R&D Pipelines
4.3 Market Restraints
4.3.1 High Cost Associated with Therapy
4.3.2 Side Effects and Complications Associated with Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Disease Type
5.1.1 Melanoma
5.1.2 Non-melanoma
5.2 By Diagnosis
5.2.1 Dermatoscopy
5.2.2 Skin Biopsy
5.2.3 Lymph Node Biopsy
5.2.4 Imaging Tests
5.2.5 Blood Tests
5.2.6 Others
5.3 By Treatment
5.3.1 Chemotherapy
5.3.2 Photodynamic Therapy
5.3.3 Immunotherapy
5.3.4 Targeted Therapy
5.3.5 Radiation Therapy
5.3.6 Other Treatments
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Abbott Laboratories.
6.1.2 Amgen, Inc.
6.1.3 Pfizer Inc.
6.1.4 Bristol-Myers Squibb Company
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Sanofi SA
6.1.7 Merck & Co., Inc.
6.1.8 Novartis AG
6.1.9 Qiagen NV
6.1.10 Sun Pharmaceutical Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories.
  • Amgen, Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Sanofi SA
  • Merck & Co., Inc.
  • Novartis AG
  • Qiagen NV
  • Sun Pharmaceutical Industries Ltd.